Medpace Holdings Inc (MEDP) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Medpace Holdings Inc (MEDP) has a cash flow conversion efficiency ratio of 0.254x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($151.79 Million) by net assets ($598.31 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See debt-free asset ratio of Medpace Holdings Inc to measure how much of total assets are equity-financed.
Medpace Holdings Inc - Cash Flow Conversion Efficiency Trend (2014–2025)
This chart illustrates how Medpace Holdings Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check MEDP operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.
Medpace Holdings Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Medpace Holdings Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
True Corporation Public Company Limited
BK:TRUE
|
0.212x |
|
Han'S Laser Tech A
SHE:002008
|
-0.006x |
|
XCMG Construction Machinery Co Ltd
SHE:000425
|
0.033x |
|
VODACOM GROUP LTD. SP.ADR
F:5VD0
|
N/A |
|
HAIER SM.HME UNSP.ADR/4
F:HAI0
|
N/A |
|
B3 S.A. - Brasil Bolsa Balcão
SA:B3SA3
|
0.081x |
|
POSCO Holdings Inc
F:PKX
|
0.031x |
|
Woori Financial Group Inc
KO:316140
|
0.118x |
Annual Cash Flow Conversion Efficiency for Medpace Holdings Inc (2014–2025)
The table below shows the annual cash flow conversion efficiency of Medpace Holdings Inc from 2014 to 2025. For the full company profile with market capitalisation and key ratios, see market value of Medpace Holdings Inc.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $459.07 Million | $713.22 Million | 1.554x | +110.67% |
| 2024-12-31 | $825.54 Million | $608.82 Million | 0.737x | -4.88% |
| 2023-12-31 | $558.95 Million | $433.37 Million | 0.775x | -22.80% |
| 2022-12-31 | $386.39 Million | $388.05 Million | 1.004x | +263.44% |
| 2021-12-31 | $952.93 Million | $263.33 Million | 0.276x | -13.92% |
| 2020-12-31 | $805.78 Million | $258.68 Million | 0.321x | +15.50% |
| 2019-12-31 | $726.28 Million | $201.87 Million | 0.278x | +4.68% |
| 2018-12-31 | $589.70 Million | $156.58 Million | 0.266x | +37.29% |
| 2017-12-31 | $503.53 Million | $97.39 Million | 0.193x | +28.76% |
| 2016-12-31 | $610.71 Million | $91.73 Million | 0.150x | -27.67% |
| 2015-12-31 | $413.47 Million | $85.87 Million | 0.208x | +11.01% |
| 2014-12-31 | $401.97 Million | $75.20 Million | 0.187x | -- |
About Medpace Holdings Inc
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, Asia, South America, Africa, and Australia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medica… Read more